Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Source filing unavailable
Q3 2013 · —
Revenue$89.10M$89.10M+33.8% vs Q3 2012 Net Income$13.49M$13.49M+103.9% vs Q3 2012 EPS Diluted$0.36$0.36+100.0% vs Q3 2012 Operating Income$18,147,000+84.9% Operating Cash Flowderived$60,125,000+29.3% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Free Cash Flowderived
Margins · derivedOperating margin20.4%+5.6 pt vs Q3 2012
Net margin15.1%+5.2 pt vs Q3 2012